0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Blood Cancer Biological Product Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-33C14661
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Blood Cancer Biological Product Market Research Report 2023
BUY CHAPTERS

Global Blood Cancer Biological Product Market Research Report 2025

Code: QYRE-Auto-33C14661
Report
May 2025
Pages:85
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Blood Cancer Biological Product Market

The global market for Blood Cancer Biological Product was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Blood Cancer Biological Product is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Blood Cancer Biological Product is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Blood Cancer Biological Product include F. Hoffmann-La Roche Ltd., Amgen, Inc., Pfizer, Inc., GSK plc., Bristol-Myers Squibb Company, Abbott, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Blood Cancer Biological Product, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Cancer Biological Product.
The Blood Cancer Biological Product market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Blood Cancer Biological Product market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Blood Cancer Biological Product manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Blood Cancer Biological Product Market Report

Report Metric Details
Report Name Blood Cancer Biological Product Market
Segment by Type
Segment by Application
  • Hospitals
  • Cancer Centers
  • Academics & Research Institutes
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company F. Hoffmann-La Roche Ltd., Amgen, Inc., Pfizer, Inc., GSK plc., Bristol-Myers Squibb Company, Abbott, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., Johnson & Johnson Services, Inc.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Blood Cancer Biological Product manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Blood Cancer Biological Product in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Blood Cancer Biological Product Market report?

Ans: The main players in the Blood Cancer Biological Product Market are F. Hoffmann-La Roche Ltd., Amgen, Inc., Pfizer, Inc., GSK plc., Bristol-Myers Squibb Company, Abbott, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., Johnson & Johnson Services, Inc.

What are the Application segmentation covered in the Blood Cancer Biological Product Market report?

Ans: The Applications covered in the Blood Cancer Biological Product Market report are Hospitals, Cancer Centers, Academics & Research Institutes

What are the Type segmentation covered in the Blood Cancer Biological Product Market report?

Ans: The Types covered in the Blood Cancer Biological Product Market report are Monoclonal Antibody, Recombinant Protein, Growth Inhibitor, Others

Recommended Reports

Blood Cancer Drugs

Cancer Therapy Solutions

Diagnostics and Testing

1 Blood Cancer Biological Product Market Overview
1.1 Product Definition
1.2 Blood Cancer Biological Product by Type
1.2.1 Global Blood Cancer Biological Product Market Value Comparison by Type (2024 VS 2031)
1.2.2 Monoclonal Antibody
1.2.3 Recombinant Protein
1.2.4 Growth Inhibitor
1.2.5 Others
1.3 Blood Cancer Biological Product by Application
1.3.1 Global Blood Cancer Biological Product Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Cancer Centers
1.3.4 Academics & Research Institutes
1.4 Global Blood Cancer Biological Product Market Size Estimates and Forecasts
1.4.1 Global Blood Cancer Biological Product Revenue 2020-2031
1.4.2 Global Blood Cancer Biological Product Sales 2020-2031
1.4.3 Global Blood Cancer Biological Product Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Blood Cancer Biological Product Market Competition by Manufacturers
2.1 Global Blood Cancer Biological Product Sales Market Share by Manufacturers (2020-2025)
2.2 Global Blood Cancer Biological Product Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Blood Cancer Biological Product Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Blood Cancer Biological Product, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Blood Cancer Biological Product, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Blood Cancer Biological Product, Product Type & Application
2.7 Global Key Manufacturers of Blood Cancer Biological Product, Date of Enter into This Industry
2.8 Global Blood Cancer Biological Product Market Competitive Situation and Trends
2.8.1 Global Blood Cancer Biological Product Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Blood Cancer Biological Product Players Market Share by Revenue
2.8.3 Global Blood Cancer Biological Product Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Blood Cancer Biological Product Market Scenario by Region
3.1 Global Blood Cancer Biological Product Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Blood Cancer Biological Product Sales by Region: 2020-2031
3.2.1 Global Blood Cancer Biological Product Sales by Region: 2020-2025
3.2.2 Global Blood Cancer Biological Product Sales by Region: 2026-2031
3.3 Global Blood Cancer Biological Product Revenue by Region: 2020-2031
3.3.1 Global Blood Cancer Biological Product Revenue by Region: 2020-2025
3.3.2 Global Blood Cancer Biological Product Revenue by Region: 2026-2031
3.4 North America Blood Cancer Biological Product Market Facts & Figures by Country
3.4.1 North America Blood Cancer Biological Product Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Blood Cancer Biological Product Sales by Country (2020-2031)
3.4.3 North America Blood Cancer Biological Product Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Blood Cancer Biological Product Market Facts & Figures by Country
3.5.1 Europe Blood Cancer Biological Product Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Blood Cancer Biological Product Sales by Country (2020-2031)
3.5.3 Europe Blood Cancer Biological Product Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Blood Cancer Biological Product Market Facts & Figures by Region
3.6.1 Asia Pacific Blood Cancer Biological Product Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Blood Cancer Biological Product Sales by Region (2020-2031)
3.6.3 Asia Pacific Blood Cancer Biological Product Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Blood Cancer Biological Product Market Facts & Figures by Country
3.7.1 Latin America Blood Cancer Biological Product Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Blood Cancer Biological Product Sales by Country (2020-2031)
3.7.3 Latin America Blood Cancer Biological Product Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Blood Cancer Biological Product Market Facts & Figures by Country
3.8.1 Middle East and Africa Blood Cancer Biological Product Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Blood Cancer Biological Product Sales by Country (2020-2031)
3.8.3 Middle East and Africa Blood Cancer Biological Product Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Blood Cancer Biological Product Sales by Type (2020-2031)
4.1.1 Global Blood Cancer Biological Product Sales by Type (2020-2025)
4.1.2 Global Blood Cancer Biological Product Sales by Type (2026-2031)
4.1.3 Global Blood Cancer Biological Product Sales Market Share by Type (2020-2031)
4.2 Global Blood Cancer Biological Product Revenue by Type (2020-2031)
4.2.1 Global Blood Cancer Biological Product Revenue by Type (2020-2025)
4.2.2 Global Blood Cancer Biological Product Revenue by Type (2026-2031)
4.2.3 Global Blood Cancer Biological Product Revenue Market Share by Type (2020-2031)
4.3 Global Blood Cancer Biological Product Price by Type (2020-2031)
5 Segment by Application
5.1 Global Blood Cancer Biological Product Sales by Application (2020-2031)
5.1.1 Global Blood Cancer Biological Product Sales by Application (2020-2025)
5.1.2 Global Blood Cancer Biological Product Sales by Application (2026-2031)
5.1.3 Global Blood Cancer Biological Product Sales Market Share by Application (2020-2031)
5.2 Global Blood Cancer Biological Product Revenue by Application (2020-2031)
5.2.1 Global Blood Cancer Biological Product Revenue by Application (2020-2025)
5.2.2 Global Blood Cancer Biological Product Revenue by Application (2026-2031)
5.2.3 Global Blood Cancer Biological Product Revenue Market Share by Application (2020-2031)
5.3 Global Blood Cancer Biological Product Price by Application (2020-2031)
6 Key Companies Profiled
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 F. Hoffmann-La Roche Ltd. Company Information
6.1.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.1.3 F. Hoffmann-La Roche Ltd. Blood Cancer Biological Product Sales, Revenue and Gross Margin (2020-2025)
6.1.4 F. Hoffmann-La Roche Ltd. Blood Cancer Biological Product Product Portfolio
6.1.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.2 Amgen, Inc.
6.2.1 Amgen, Inc. Company Information
6.2.2 Amgen, Inc. Description and Business Overview
6.2.3 Amgen, Inc. Blood Cancer Biological Product Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Amgen, Inc. Blood Cancer Biological Product Product Portfolio
6.2.5 Amgen, Inc. Recent Developments/Updates
6.3 Pfizer, Inc.
6.3.1 Pfizer, Inc. Company Information
6.3.2 Pfizer, Inc. Description and Business Overview
6.3.3 Pfizer, Inc. Blood Cancer Biological Product Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer, Inc. Blood Cancer Biological Product Product Portfolio
6.3.5 Pfizer, Inc. Recent Developments/Updates
6.4 GSK plc.
6.4.1 GSK plc. Company Information
6.4.2 GSK plc. Description and Business Overview
6.4.3 GSK plc. Blood Cancer Biological Product Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GSK plc. Blood Cancer Biological Product Product Portfolio
6.4.5 GSK plc. Recent Developments/Updates
6.5 Bristol-Myers Squibb Company
6.5.1 Bristol-Myers Squibb Company Company Information
6.5.2 Bristol-Myers Squibb Company Description and Business Overview
6.5.3 Bristol-Myers Squibb Company Blood Cancer Biological Product Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bristol-Myers Squibb Company Blood Cancer Biological Product Product Portfolio
6.5.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.6 Abbott
6.6.1 Abbott Company Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Blood Cancer Biological Product Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Abbott Blood Cancer Biological Product Product Portfolio
6.6.5 Abbott Recent Developments/Updates
6.7 AstraZeneca
6.7.1 AstraZeneca Company Information
6.7.2 AstraZeneca Description and Business Overview
6.7.3 AstraZeneca Blood Cancer Biological Product Sales, Revenue and Gross Margin (2020-2025)
6.7.4 AstraZeneca Blood Cancer Biological Product Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Eli Lilly and Company
6.8.1 Eli Lilly and Company Company Information
6.8.2 Eli Lilly and Company Description and Business Overview
6.8.3 Eli Lilly and Company Blood Cancer Biological Product Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Eli Lilly and Company Blood Cancer Biological Product Product Portfolio
6.8.5 Eli Lilly and Company Recent Developments/Updates
6.9 Gilead Sciences, Inc.
6.9.1 Gilead Sciences, Inc. Company Information
6.9.2 Gilead Sciences, Inc. Description and Business Overview
6.9.3 Gilead Sciences, Inc. Blood Cancer Biological Product Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Gilead Sciences, Inc. Blood Cancer Biological Product Product Portfolio
6.9.5 Gilead Sciences, Inc. Recent Developments/Updates
6.10 Johnson & Johnson Services, Inc.
6.10.1 Johnson & Johnson Services, Inc. Company Information
6.10.2 Johnson & Johnson Services, Inc. Description and Business Overview
6.10.3 Johnson & Johnson Services, Inc. Blood Cancer Biological Product Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Johnson & Johnson Services, Inc. Blood Cancer Biological Product Product Portfolio
6.10.5 Johnson & Johnson Services, Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Blood Cancer Biological Product Industry Chain Analysis
7.2 Blood Cancer Biological Product Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Blood Cancer Biological Product Production Mode & Process Analysis
7.4 Blood Cancer Biological Product Sales and Marketing
7.4.1 Blood Cancer Biological Product Sales Channels
7.4.2 Blood Cancer Biological Product Distributors
7.5 Blood Cancer Biological Product Customer Analysis
8 Blood Cancer Biological Product Market Dynamics
8.1 Blood Cancer Biological Product Industry Trends
8.2 Blood Cancer Biological Product Market Drivers
8.3 Blood Cancer Biological Product Market Challenges
8.4 Blood Cancer Biological Product Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Blood Cancer Biological Product Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Blood Cancer Biological Product Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Blood Cancer Biological Product Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Blood Cancer Biological Product Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Blood Cancer Biological Product Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Blood Cancer Biological Product Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Blood Cancer Biological Product Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Blood Cancer Biological Product Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Blood Cancer Biological Product, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Blood Cancer Biological Product, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Blood Cancer Biological Product, Product Type & Application
 Table 12. Global Key Manufacturers of Blood Cancer Biological Product, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Blood Cancer Biological Product by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Biological Product as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Blood Cancer Biological Product Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Blood Cancer Biological Product Sales by Region (2020-2025) & (K Units)
 Table 18. Global Blood Cancer Biological Product Sales Market Share by Region (2020-2025)
 Table 19. Global Blood Cancer Biological Product Sales by Region (2026-2031) & (K Units)
 Table 20. Global Blood Cancer Biological Product Sales Market Share by Region (2026-2031)
 Table 21. Global Blood Cancer Biological Product Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Blood Cancer Biological Product Revenue Market Share by Region (2020-2025)
 Table 23. Global Blood Cancer Biological Product Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Blood Cancer Biological Product Revenue Market Share by Region (2026-2031)
 Table 25. North America Blood Cancer Biological Product Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Blood Cancer Biological Product Sales by Country (2020-2025) & (K Units)
 Table 27. North America Blood Cancer Biological Product Sales by Country (2026-2031) & (K Units)
 Table 28. North America Blood Cancer Biological Product Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Blood Cancer Biological Product Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Blood Cancer Biological Product Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Blood Cancer Biological Product Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Blood Cancer Biological Product Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Blood Cancer Biological Product Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Blood Cancer Biological Product Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Blood Cancer Biological Product Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Blood Cancer Biological Product Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Blood Cancer Biological Product Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Blood Cancer Biological Product Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Blood Cancer Biological Product Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Blood Cancer Biological Product Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Blood Cancer Biological Product Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Blood Cancer Biological Product Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Blood Cancer Biological Product Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Blood Cancer Biological Product Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Blood Cancer Biological Product Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Blood Cancer Biological Product Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Blood Cancer Biological Product Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Blood Cancer Biological Product Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Blood Cancer Biological Product Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Blood Cancer Biological Product Sales (K Units) by Type (2020-2025)
 Table 51. Global Blood Cancer Biological Product Sales (K Units) by Type (2026-2031)
 Table 52. Global Blood Cancer Biological Product Sales Market Share by Type (2020-2025)
 Table 53. Global Blood Cancer Biological Product Sales Market Share by Type (2026-2031)
 Table 54. Global Blood Cancer Biological Product Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Blood Cancer Biological Product Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Blood Cancer Biological Product Revenue Market Share by Type (2020-2025)
 Table 57. Global Blood Cancer Biological Product Revenue Market Share by Type (2026-2031)
 Table 58. Global Blood Cancer Biological Product Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Blood Cancer Biological Product Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Blood Cancer Biological Product Sales (K Units) by Application (2020-2025)
 Table 61. Global Blood Cancer Biological Product Sales (K Units) by Application (2026-2031)
 Table 62. Global Blood Cancer Biological Product Sales Market Share by Application (2020-2025)
 Table 63. Global Blood Cancer Biological Product Sales Market Share by Application (2026-2031)
 Table 64. Global Blood Cancer Biological Product Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Blood Cancer Biological Product Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Blood Cancer Biological Product Revenue Market Share by Application (2020-2025)
 Table 67. Global Blood Cancer Biological Product Revenue Market Share by Application (2026-2031)
 Table 68. Global Blood Cancer Biological Product Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Blood Cancer Biological Product Price (US$/Unit) by Application (2026-2031)
 Table 70. F. Hoffmann-La Roche Ltd. Company Information
 Table 71. F. Hoffmann-La Roche Ltd. Description and Business Overview
 Table 72. F. Hoffmann-La Roche Ltd. Blood Cancer Biological Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. F. Hoffmann-La Roche Ltd. Blood Cancer Biological Product Product
 Table 74. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
 Table 75. Amgen, Inc. Company Information
 Table 76. Amgen, Inc. Description and Business Overview
 Table 77. Amgen, Inc. Blood Cancer Biological Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Amgen, Inc. Blood Cancer Biological Product Product
 Table 79. Amgen, Inc. Recent Developments/Updates
 Table 80. Pfizer, Inc. Company Information
 Table 81. Pfizer, Inc. Description and Business Overview
 Table 82. Pfizer, Inc. Blood Cancer Biological Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Pfizer, Inc. Blood Cancer Biological Product Product
 Table 84. Pfizer, Inc. Recent Developments/Updates
 Table 85. GSK plc. Company Information
 Table 86. GSK plc. Description and Business Overview
 Table 87. GSK plc. Blood Cancer Biological Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. GSK plc. Blood Cancer Biological Product Product
 Table 89. GSK plc. Recent Developments/Updates
 Table 90. Bristol-Myers Squibb Company Company Information
 Table 91. Bristol-Myers Squibb Company Description and Business Overview
 Table 92. Bristol-Myers Squibb Company Blood Cancer Biological Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Bristol-Myers Squibb Company Blood Cancer Biological Product Product
 Table 94. Bristol-Myers Squibb Company Recent Developments/Updates
 Table 95. Abbott Company Information
 Table 96. Abbott Description and Business Overview
 Table 97. Abbott Blood Cancer Biological Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Abbott Blood Cancer Biological Product Product
 Table 99. Abbott Recent Developments/Updates
 Table 100. AstraZeneca Company Information
 Table 101. AstraZeneca Description and Business Overview
 Table 102. AstraZeneca Blood Cancer Biological Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. AstraZeneca Blood Cancer Biological Product Product
 Table 104. AstraZeneca Recent Developments/Updates
 Table 105. Eli Lilly and Company Company Information
 Table 106. Eli Lilly and Company Description and Business Overview
 Table 107. Eli Lilly and Company Blood Cancer Biological Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Eli Lilly and Company Blood Cancer Biological Product Product
 Table 109. Eli Lilly and Company Recent Developments/Updates
 Table 110. Gilead Sciences, Inc. Company Information
 Table 111. Gilead Sciences, Inc. Description and Business Overview
 Table 112. Gilead Sciences, Inc. Blood Cancer Biological Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Gilead Sciences, Inc. Blood Cancer Biological Product Product
 Table 114. Gilead Sciences, Inc. Recent Developments/Updates
 Table 115. Johnson & Johnson Services, Inc. Company Information
 Table 116. Johnson & Johnson Services, Inc. Description and Business Overview
 Table 117. Johnson & Johnson Services, Inc. Blood Cancer Biological Product Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Johnson & Johnson Services, Inc. Blood Cancer Biological Product Product
 Table 119. Johnson & Johnson Services, Inc. Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Blood Cancer Biological Product Distributors List
 Table 123. Blood Cancer Biological Product Customers List
 Table 124. Blood Cancer Biological Product Market Trends
 Table 125. Blood Cancer Biological Product Market Drivers
 Table 126. Blood Cancer Biological Product Market Challenges
 Table 127. Blood Cancer Biological Product Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Blood Cancer Biological Product
 Figure 2. Global Blood Cancer Biological Product Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Blood Cancer Biological Product Market Share by Type: 2024 & 2031
 Figure 4. Monoclonal Antibody Product Picture
 Figure 5. Recombinant Protein Product Picture
 Figure 6. Growth Inhibitor Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Blood Cancer Biological Product Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Blood Cancer Biological Product Market Share by Application: 2024 & 2031
 Figure 10. Hospitals
 Figure 11. Cancer Centers
 Figure 12. Academics & Research Institutes
 Figure 13. Global Blood Cancer Biological Product Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Blood Cancer Biological Product Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Blood Cancer Biological Product Sales (2020-2031) & (K Units)
 Figure 16. Global Blood Cancer Biological Product Average Price (US$/Unit) & (2020-2031)
 Figure 17. Blood Cancer Biological Product Report Years Considered
 Figure 18. Blood Cancer Biological Product Sales Share by Manufacturers in 2024
 Figure 19. Global Blood Cancer Biological Product Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Blood Cancer Biological Product Players: Market Share by Revenue in Blood Cancer Biological Product in 2024
 Figure 21. Blood Cancer Biological Product Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Blood Cancer Biological Product Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Blood Cancer Biological Product Sales Market Share by Country (2020-2031)
 Figure 24. North America Blood Cancer Biological Product Revenue Market Share by Country (2020-2031)
 Figure 25. United States Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Blood Cancer Biological Product Sales Market Share by Country (2020-2031)
 Figure 28. Europe Blood Cancer Biological Product Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Blood Cancer Biological Product Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Blood Cancer Biological Product Revenue Market Share by Region (2020-2031)
 Figure 36. China Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Blood Cancer Biological Product Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Blood Cancer Biological Product Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Blood Cancer Biological Product Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Blood Cancer Biological Product Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Blood Cancer Biological Product Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Blood Cancer Biological Product by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Blood Cancer Biological Product by Type (2020-2031)
 Figure 55. Global Blood Cancer Biological Product Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Blood Cancer Biological Product by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Blood Cancer Biological Product by Application (2020-2031)
 Figure 58. Global Blood Cancer Biological Product Price (US$/Unit) by Application (2020-2031)
 Figure 59. Blood Cancer Biological Product Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS